Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$76.51 USD
+3.01 (4.10%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $76.74 +0.23 (0.30%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Brokerage Reports
0 items in cart
Gilead Sciences, Inc. [GILD]
Reports for Purchase
Showing records 521 - 529 ( 529 total )
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Reports 4Q09 Earnings; Maintain Neutral
Provider: MERRIMAN CURHAN FORD & CO.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Q4:09 Beats on Both Top and Bottom Line; 2010 Guidance Ahead of Current Consensus
Provider: WEDBUSH SECURITIES INC.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Previewing 4Q09:What to Watch for in 2010; Maintain Neutral
Provider: MERRIMAN CURHAN FORD & CO.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Q4:09 Preview
Provider: WEDBUSH SECURITIES INC.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Biotech Balance Sheet
Provider: MERRIMAN CURHAN FORD & CO.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Life Sciences - Biotechnology - Biotech Balance Sheet
Provider: MERRIMAN CURHAN FORD & CO.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Biotech Balance Sheet
Provider: MERRIMAN CURHAN FORD & CO.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Topline Phase II Quad vs. Atripla Meets Expectations
Provider: WEDBUSH SECURITIES INC.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Biotech Balance Sheet
Provider: MERRIMAN CURHAN FORD & CO.